Aptahem AB (publ) (NGM:APTA)
0.5260
+0.0260 (5.20%)
At close: Sep 3, 2026
Aptahem AB Earnings Call Transcripts
Fiscal Year 2025
-
A lead RNA aptamer for sepsis is advancing toward phase 2, with strong preclinical and phase 1 data. U.S. listing preparations are underway to access better valuation and regulatory incentives, while partnerships and expanded IP are being pursued for broader impact.